CD4 and melanoma: As melanoma helper peptides were identified, we developed a vaccine comprising 6 melanoma peptides presented by Class II HLA-DR molecules (6 melanoma helper peptides, 6MHP, NSC#728926), which induced Th1-dominant CD4+ T cell responses in most patients and induced durable clinical activity in some7,8.